The estimated Net Worth of Jeffrey Gold is at least $593 Mille dollars as of 12 July 2019. Jeffrey Gold owns over 6,650 units of Angiodynamic Inc stock worth over $592,554 and over the last 20 years Jeffrey sold ANGO stock worth over $0.
Jeffrey has made over 12 trades of the Angiodynamic Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Jeffrey exercised 6,650 units of ANGO stock worth $71,022 on 12 July 2019.
The largest trade Jeffrey's ever made was buying 15,000 units of Angiodynamic Inc stock on 16 May 2018 worth over $12,000. On average, Jeffrey trades about 2,367 units every 71 days since 2004. As of 12 July 2019 Jeffrey still owns at least 79,859 units of Angiodynamic Inc stock.
You can see the complete history of Jeffrey Gold stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman e Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: